{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T21:18:43Z","timestamp":1792703923813,"version":"4.5.0"},"reference-count":79,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T00:00:00Z","timestamp":1773100800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","euoncology.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Oncology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.euo.2026.03.005","type":"journal-article","created":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T16:37:37Z","timestamp":1773938257000},"page":"690-704","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Blood and Urine Circulating Tumor DNA in Urothelial Bladder Cancer: State of the Art and Clinical Perspective"],"prefix":"10.1016","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6716-6473","authenticated-orcid":false,"given":"Igor","family":"Duquesne","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Epelbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doriane","family":"Prost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathilde","family":"Haberstich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caio Vin\u00edcius","family":"Suartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9l\u00e8ne","family":"Blons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Taly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Laurent-Puig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir","family":"Horowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John P.","family":"Sfakianos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constance","family":"Thibault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Audenet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euo.2026.03.005_b0005","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.euo.2026.03.005_b0010","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.ejca.2018.08.003","article-title":"Image-guided tumour biopsies in a prospective molecular triage study (MOSCATO-01): what are the real risks?","volume":"103","author":"Prud\u2019homme","year":"2018","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.euo.2026.03.005_b0015","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1056\/NEJMra1706174","article-title":"Application of cell-free DNA analysis to cancer treatment","volume":"379","author":"Corcoran","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2026.03.005_b0020","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2012.45.2011","article-title":"Liquid biopsies: genotyping circulating tumor DNA","volume":"32","author":"Diaz","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2026.03.005_b0025","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/nrc.2017.7","article-title":"Liquid biopsies come of age: towards implementation of circulating tumour DNA","volume":"17","author":"Wan","year":"2017","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.euo.2026.03.005_b0030","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/s12913-021-06122-y","article-title":"Quality assessment with diverse studies (QuADS): an appraisal tool for methodological and reporting quality in systematic reviews of mixed- or multi-method studies","volume":"21","author":"Harrison","year":"2021","journal-title":"BMC Health Serv Res"},{"key":"10.1016\/j.euo.2026.03.005_b0035","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/s41467-020-20493-6","article-title":"Plasma ctDNA is a tumor tissue surrogate and enables clinical-genomic stratification of metastatic bladder cancer","volume":"12","author":"Vandekerkhove","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.euo.2026.03.005_b0040","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1038\/nm.1789","article-title":"Circulating mutant DNA to assess tumor dynamics","volume":"14","author":"Diehl","year":"2008","journal-title":"Nat Med"},{"key":"10.1016\/j.euo.2026.03.005_b0045","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1039\/C8LC00100F","article-title":"Circulating tumor DNA and liquid biopsy: opportunities, challenges, and recent advances in detection technologies","volume":"18","author":"Gorgannezhad","year":"2018","journal-title":"Lab Chip"},{"key":"10.1016\/j.euo.2026.03.005_b0050","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1016\/j.medj.2021.11.001","article-title":"Liquid biopsies for residual disease and recurrence","volume":"2","author":"Wan","year":"2021","journal-title":"Med"},{"key":"10.1016\/j.euo.2026.03.005_b0055","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1080\/14737159.2019.1568873","article-title":"Technical considerations for circulating tumor DNA detection in oncology","volume":"19","author":"Franczak","year":"2019","journal-title":"Expert Rev Mol Diagn"},{"key":"10.1016\/j.euo.2026.03.005_b0060","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","article-title":"European Association of Urology guidelines on non-muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ)","volume":"81","author":"Babjuk","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2026.03.005_b0065","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.ejso.2004.12.008","article-title":"The role of urinary cytology for detection of bladder cancer","volume":"31","author":"Planz","year":"2005","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.euo.2026.03.005_b0070","first-page":"779","article-title":"Serum DNA hypermethylation in patients with bladder cancer: results of a prospective multicenter study","volume":"33","author":"Hauser","year":"2013","journal-title":"Anticancer Res"},{"key":"10.1016\/j.euo.2026.03.005_b0075","article-title":"Circulating tumor DNA analyses predict disease recurrence in non-muscle-invasive bladder cancer","volume":"11","author":"Zhang","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.euo.2026.03.005_b0080","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1200\/JCO.18.02052","article-title":"Early detection of metastatic relapse and monitoring of therapeutic efficacy by ultra-deep sequencing of plasma cell-free DNA in patients with urothelial bladder carcinoma","volume":"37","author":"Christensen","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2026.03.005_b0085","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.eururo.2016.12.016","article-title":"Liquid biopsy analysis of FGFR3 and PIK3CA hotspot mutations for disease surveillance in bladder cancer","volume":"71","author":"Christensen","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2026.03.005_b0090","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1002\/path.2507","article-title":"The development of multiple bladder tumour recurrences in relation to the FGFR3 mutation status of the primary tumour","volume":"218","author":"Kompier","year":"2009","journal-title":"J Pathol"},{"key":"10.1016\/j.euo.2026.03.005_b0095","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.eururo.2016.01.007","article-title":"Genomic alterations in liquid biopsies from patients with bladder cancer","volume":"70","author":"Birkenkamp-Demtr\u00f6der","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2026.03.005_b0100","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1111\/bju.16556","article-title":"Undetectable pre-radical cystectomy circulating tumour DNA status predicts improved oncological outcomes","volume":"135","author":"Ben-David","year":"2025","journal-title":"BJU Int"},{"key":"10.1016\/j.euo.2026.03.005_b0105","unstructured":"Haberstich M, Pignot G, Rigaud J, et al. 1762. MERINOS: metastatic non muscle invasive urothelial carcinoma \u2013 an observational study; n.d."},{"key":"10.1016\/j.euo.2026.03.005_b0110","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.euo.2025.05.019","article-title":"Real-world experience with a commercial circulating tumor DNA assay in non-muscle-invasive bladder cancer","volume":"8","author":"Wang","year":"2025","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euo.2026.03.005_b0115","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.eururo.2020.03.055","article-title":"European Association of Urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2020 guidelines","volume":"79","author":"Witjes","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2026.03.005_b0120","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/s41586-021-03642-9","article-title":"ctDNA guiding adjuvant immunotherapy in urothelial carcinoma","volume":"595","author":"Powles","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.euo.2026.03.005_b0125","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.eururo.2023.06.007","article-title":"Updated overall survival by circulating tumor DNA status from the phase 3 IMvigor010 trial: adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma","volume":"85","author":"Powles","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2026.03.005_b0130","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.eururo.2022.04.013","article-title":"Final results of neoadjuvant atezolizumab in cisplatin-ineligible patients with muscle-invasive urothelial cancer of the bladder","volume":"82","author":"Szabados","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2026.03.005_b0135","doi-asserted-by":"crossref","first-page":"5554","DOI":"10.1038\/s41598-017-05623-3","article-title":"Association of plasma and urinary mutant DNA with clinical outcomes in muscle invasive bladder cancer","volume":"7","author":"Patel","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.euo.2026.03.005_b0140","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.euo.2023.03.008","article-title":"Cell-free DNA methylation as a predictive biomarker of response to neoadjuvant chemotherapy for patients with muscle-invasive bladder cancer in SWOG S1314","volume":"6","author":"Lu","year":"2023","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euo.2026.03.005_b0145","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.eururo.2017.09.011","article-title":"Monitoring treatment response and metastatic relapse in advanced bladder cancer by liquid biopsy analysis","volume":"73","author":"Birkenkamp-Demtr\u00f6der","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2026.03.005_b0150","doi-asserted-by":"crossref","first-page":"4589","DOI":"10.1200\/JCO.2023.41.16_suppl.4589","article-title":"Accuracy of genome-wide mutational analysis for tumor-informed ctDNA-guided MRD monitoring in bladder cancer","volume":"41","author":"Nordentoft","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2026.03.005_b0155","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/j.euo.2024.03.002","article-title":"Longitudinal tumor-informed circulating tumor DNA status predicts disease upstaging and poor prognosis for patients undergoing radical cystectomy","volume":"7","author":"Ben-David","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euo.2026.03.005_b0160","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1093\/clinchem\/hvac218","article-title":"Preoperative cell-free DNA (cfDNA) in muscle-invasive bladder cancer treatment outcome","volume":"69","author":"Papadimitriou","year":"2023","journal-title":"Clin Chem"},{"key":"10.1016\/j.euo.2026.03.005_b0165","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.euo.2024.07.001","article-title":"Association of tumor-informed circulating tumor DNA detectability before and after radical cystectomy with disease-free survival in patients with bladder cancer","volume":"8","author":"Sfakianos","year":"2025","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euo.2026.03.005_b0170","doi-asserted-by":"crossref","first-page":"11732","DOI":"10.3390\/ijms231911732","article-title":"Cell-free DNA as a prognostic biomarker for monitoring muscle-invasive bladder cancer","volume":"23","author":"Carrasco","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.euo.2026.03.005_b0175","doi-asserted-by":"crossref","first-page":"16578","DOI":"10.3390\/ijms242316578","article-title":"Tumor-agnostic circulating tumor DNA testing for monitoring muscle-invasive bladder cancer","volume":"24","author":"Carrasco","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.euo.2026.03.005_b0180","doi-asserted-by":"crossref","first-page":"56398","DOI":"10.18632\/oncotarget.17657","article-title":"Copy number variations of circulating, cell-free DNA in urothelial carcinoma of the bladder patients treated with radical cystectomy: a prospective study","volume":"8","author":"Soave","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.euo.2026.03.005_b0185","doi-asserted-by":"crossref","first-page":"4602","DOI":"10.1200\/JCO.2025.43.16_suppl.4602","article-title":"Correlation of circulating tumor DNA (ctDNA) dynamics with clinical response in muscle-invasive bladder cancer (MIBC) patients (pts) undergoing trimodality therapy (TMT)","volume":"43","author":"Epstein","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2026.03.005_b0190","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1002\/cncr.31314","article-title":"Characterization of metastatic urothelial carcinoma via comprehensive genomic profiling of circulating tumor DNA","volume":"124","author":"Agarwal","year":"2018","journal-title":"Cancer"},{"key":"10.1016\/j.euo.2026.03.005_b0195","doi-asserted-by":"crossref","first-page":"6487","DOI":"10.1158\/1078-0432.CCR-17-1140","article-title":"Circulating tumor DNA reveals clinically actionable somatic genome of metastatic bladder cancer","volume":"23","author":"Vandekerkhove","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.euo.2026.03.005_b0200","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.euo.2019.02.004","article-title":"Circulating tumor DNA alterations in advanced urothelial carcinoma and association with clinical outcomes: A pilot study","volume":"3","author":"Grivas","year":"2020","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euo.2026.03.005_b0205","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/s41416-021-01648-8","article-title":"Serial ctDNA analysis predicts clinical progression in patients with advanced urothelial carcinoma","volume":"126","author":"Shohdy","year":"2022","journal-title":"Br J Cancer"},{"key":"10.1016\/j.euo.2026.03.005_b0210","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.1002\/cncr.32806","article-title":"Infigratinib in upper tract urothelial carcinoma versus urothelial carcinoma of the bladder and its association with comprehensive genomic profiling and\/or cell-free DNA results","volume":"126","author":"Pal","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.euo.2026.03.005_b0215","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/s41591-021-01317-6","article-title":"An adaptive, biomarker-directed platform study of durvalumab in combination with targeted therapies in advanced urothelial cancer","volume":"27","author":"Powles","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.euo.2026.03.005_b0220","doi-asserted-by":"crossref","first-page":"e406","DOI":"10.1093\/oncolo\/oyac037","article-title":"Longitudinal evaluation of circulating tumor DNA using sensitive amplicon-based next-generation sequencing to identify resistance mechanisms to immune checkpoint inhibitors for advanced urothelial carcinoma","volume":"27","author":"Ravi","year":"2022","journal-title":"Oncologist"},{"key":"10.1016\/j.euo.2026.03.005_b0225","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1002\/1878-0261.13196","article-title":"Genome-wide aneuploidy detected by mFast-SeqS in circulating cell-free DNA is associated with poor response to pembrolizumab in patients with advanced urothelial cancer","volume":"16","author":"Mendelaar","year":"2022","journal-title":"Mol Oncol"},{"key":"10.1016\/j.euo.2026.03.005_b0230","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1002\/path.6166","article-title":"Integrated longitudinal circulating tumor DNA profiling predicts immunotherapy response of metastatic urothelial carcinoma in the POLARIS-03 trial","volume":"261","author":"Zang","year":"2023","journal-title":"J Pathol"},{"key":"10.1016\/j.euo.2026.03.005_b0235","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1200\/JCO.2018.36.6_suppl.453","article-title":"Correlation of circulating tumor DNA (ctDNA) assessment with tissue-based comprehensive genomic profiling (CGP) in metastatic urothelial cancer (mUC)","volume":"36","author":"McGregor","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2026.03.005_b0240","doi-asserted-by":"crossref","first-page":"389","DOI":"10.3892\/ol.2023.13975","article-title":"Variant allele frequency changes in TP53 predict pembrolizumab response in patients with metastatic urothelial carcinoma","volume":"26","author":"Hamada","year":"2023","journal-title":"Oncol Lett"},{"key":"10.1016\/j.euo.2026.03.005_b0245","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.113368","article-title":"Clinical utility of plasma ctDNA sequencing in metastatic urothelial cancer","volume":"195","author":"Helal","year":"2023","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.euo.2026.03.005_b0250","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1038\/s41585-023-00725-2","article-title":"Circulating and urinary tumour DNA in urothelial carcinoma \u2013 upper tract, lower tract and metastatic disease","volume":"20","author":"Rose","year":"2023","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.euo.2026.03.005_b0255","article-title":"Development of a technique for diagnosis and screening of superficial bladder cancer by cell-pellet DNA from urine sample","volume":"105","author":"Seok","year":"2025","journal-title":"Lab Invest"},{"key":"10.1016\/j.euo.2026.03.005_b0260","doi-asserted-by":"crossref","first-page":"3235","DOI":"10.1111\/cas.14155","article-title":"Genomic profile of urine has high diagnostic sensitivity compared to cytology in non-invasive urothelial bladder cancer","volume":"110","author":"Hirotsu","year":"2019","journal-title":"Cancer Sci"},{"key":"10.1016\/j.euo.2026.03.005_b0265","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s40169-020-0257-2","article-title":"Detection of bladder cancer using urinary cell-free DNA and cellular DNA","volume":"9","author":"Ou","year":"2020","journal-title":"Clin Transl Med"},{"key":"10.1016\/j.euo.2026.03.005_b0270","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.ebiom.2019.05.004","article-title":"Urinary TERT promoter mutations as non-invasive biomarkers for the comprehensive detection of urothelial cancer","volume":"44","author":"Avogbe","year":"2019","journal-title":"EBiomedicine"},{"key":"10.1016\/j.euo.2026.03.005_b0275","doi-asserted-by":"crossref","first-page":"755","DOI":"10.3389\/fonc.2020.00755","article-title":"Clinical significance of hotspot mutation analysis of urinary cell-free DNA in urothelial bladder cancer","volume":"10","author":"Hayashi","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.euo.2026.03.005_b0280","article-title":"UriFind assay and association with whole course management of urothelial carcinoma in a large multicentric, prospective China cohort","volume":"41","author":"Chen","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2026.03.005_b0285","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1200\/JCO.2025.43.5_suppl.860","article-title":"Comprehensive bladder cancer molecular profiling and monitoring based on mutational, epigenomic, and expression data from real-world patients","volume":"43","author":"Tan","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2026.03.005_b0290","doi-asserted-by":"crossref","first-page":"3668","DOI":"10.1158\/1078-0432.CCR-23-0570","article-title":"Development and multicenter case-control validation of urinary comprehensive genomic profiling for urothelial carcinoma diagnosis, surveillance, and risk-prediction","volume":"29","author":"Salari","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.euo.2026.03.005_b0295","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s12943-024-01974-4","article-title":"Clinical effectiveness of a multitarget urine DNA test for urothelial carcinoma detection: a double-blinded, multicenter, prospective trial","volume":"23","author":"Wu","year":"2024","journal-title":"Mol Cancer"},{"key":"10.1016\/j.euo.2026.03.005_b0300","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1158\/2159-8290.CD-18-0825","article-title":"Detection and surveillance of bladder cancer using urine tumor DNA","volume":"9","author":"Dudley","year":"2019","journal-title":"Cancer Discov"},{"key":"10.1016\/j.euo.2026.03.005_b0305","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41698-022-00345-w","article-title":"Urine cell-free DNA multi-omics to detect MRD and predict survival in bladder cancer patients","volume":"7","author":"Chauhan","year":"2023","journal-title":"NPJ Precis Oncol"},{"key":"10.1016\/j.euo.2026.03.005_b0310","doi-asserted-by":"crossref","first-page":"18","DOI":"10.3892\/ijo.2025.5724","article-title":"Unleashing the power of urine-based biomarkers in diagnosis, prognosis and monitoring of bladder cancer (review)","volume":"66","author":"Wan","year":"2025","journal-title":"Int J Oncol"},{"key":"10.1016\/j.euo.2026.03.005_b0315","doi-asserted-by":"crossref","first-page":"4584","DOI":"10.1200\/JCO.2025.43.16_suppl.4584","article-title":"Revolutionizing bladder cancer follow-up: personalized urinary ctDNA analysis for detecting minimal residual disease","volume":"43","author":"Wan","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2026.03.005_b0320","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.euo.2022.03.005","article-title":"Highly sensitive and specific detection of bladder cancer via targeted ultra-deep sequencing of urinary DNA","volume":"6","author":"Ward","year":"2023","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euo.2026.03.005_b0325","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.e16580","article-title":"Comparison of clinical outcomes of bladder preservation and surgery in a real-world study of patients with muscle invasive urothelial carcinoma using urine and plasma based MRD (minimal residual disease) assays","volume":"42","author":"Au","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2026.03.005_b0330","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1158\/1078-0432.CCR-22-3250","article-title":"Cell-free urine and plasma DNA mutational analysis predicts neoadjuvant chemotherapy response and outcome in patients with muscle-invasive bladder cancer","volume":"29","author":"Christensen","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.euo.2026.03.005_b0335","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/j.eururo.2006.12.019","article-title":"Urinary CYFRA 21.1 is not a useful marker for the detection of recurrences in the follow-up of superficial bladder cancer","volume":"51","author":"Fernandez-Gomez","year":"2007","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2026.03.005_b0340","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/s41585-020-0304-1","article-title":"Genomic heterogeneity in bladder cancer: challenges and possible solutions to improve outcomes","volume":"17","author":"Meeks","year":"2020","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.euo.2026.03.005_b0345","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1097\/PAP.0b013e3181832320","article-title":"Bladder cancer detection using FISH (UroVysion assay)","volume":"15","author":"Halling","year":"2008","journal-title":"Adv Anat Pathol"},{"key":"10.1016\/j.euo.2026.03.005_b0350","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1007\/s00345-018-2543-9","article-title":"The current role and future directions of circulating tumor cells and circulating tumor DNA in urothelial carcinoma of the bladder","volume":"37","author":"Rink","year":"2019","journal-title":"World J Urol"},{"key":"10.1016\/j.euo.2026.03.005_b0355","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.21037\/tau.2017.09.16","article-title":"The current status and clinical value of circulating tumor cells and circulating cell-free tumor DNA in bladder cancer","volume":"6","author":"Riethdorf","year":"2017","journal-title":"Transl Androl Urol"},{"issue":"Suppl. 1","key":"10.1016\/j.euo.2026.03.005_b0360","doi-asserted-by":"crossref","first-page":"S101","DOI":"10.21037\/tau.2018.01.01","article-title":"Detection of circulating tumor DNA for advanced bladder cancer: where are we going?","volume":"7","author":"Morales-Barrera","year":"2018","journal-title":"Transl Androl Urol"},{"key":"10.1016\/j.euo.2026.03.005_b0365","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.euo.2023.05.012","article-title":"Circulating tumor DNA as a predictive and prognostic biomarker in the perioperative treatment of muscle-invasive bladder cancer: a systematic review","volume":"7","author":"Crupi","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euo.2026.03.005_b0370","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.186062","article-title":"Multimodal integration of blood RNA and ctDNA reflects response to immunotherapy in metastatic urothelial cancer","volume":"10","author":"van Wilpe","year":"2025","journal-title":"JCI Insight"},{"key":"10.1016\/j.euo.2026.03.005_b0375","article-title":"Clinical utility of serial circulating tumor DNA analysis as a minimally invasive biomarker in advanced urothelial cancer","volume":"9","author":"Sakatani","year":"2025","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.euo.2026.03.005_b0380","doi-asserted-by":"crossref","first-page":"4797","DOI":"10.1158\/1078-0432.CCR-23-1860","article-title":"Circulating tumor DNA analysis in advanced urothelial carcinoma: insights from biological analysis and extended clinical follow-up","volume":"29","author":"Lindskrog","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.euo.2026.03.005_b0385","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1056\/NEJMoa2511885","article-title":"ctDNA-guided adjuvant atezolizumab in muscle-invasive bladder cancer","volume":"393","author":"Powles","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2026.03.005_b0390","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1056\/NEJMoa2408154","article-title":"Perioperative durvalumab with neoadjuvant chemotherapy in operable bladder cancer","volume":"391","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2026.03.005_b0395","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2023.101763","article-title":"Circulating tumor DNA based minimal residual disease detection and adjuvant treatment decision-making for muscle-invasive bladder cancer guided by modern clinical trials","volume":"37","author":"Nawaf","year":"2023","journal-title":"Transl Oncol"}],"container-title":["European Urology Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931126000659?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931126000659?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T20:43:42Z","timestamp":1783197822000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2588931126000659"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":79,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S2588931126000659"],"URL":"https:\/\/doi.org\/10.1016\/j.euo.2026.03.005","relation":{},"ISSN":["2588-9311"],"issn-type":[{"value":"2588-9311","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Blood and Urine Circulating Tumor DNA in Urothelial Bladder Cancer: State of the Art and Clinical Perspective","name":"articletitle","label":"Article Title"},{"value":"European Urology Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euo.2026.03.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}